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Abstract:
Introduction: Cystic Fibrosis (CF) is an autosomal recessive disorder with serious

pulmonary and nutritional implications. Nutrition status has a direct affect on lung
function and longevity. Screening patients for growth velocity makes it possible to
identify patients at nutritional risk . This identification is the first step towards
appropriate nutritional interventions . The current screening tool used for children and
adolescents with CF is not reliable and leaves too much room for clinical judgment. It is
for this reason that a new screening tool was developed. Methods: The Cystic Fibrosis
Foundation established a panel of experts for the purpose of developing an evidence
based screening tool to be used for children and adolescents with CF aged 2 to 20 years .
Catherine McDonald, PhD , RD, was then given the responsibility to develop the actual
tool and solicit feedback from other clinical nutrition experts. This feedback included a
qualitative feedback questionnaire and a validation survey. The qualitative comments
were used to edit and revise the tool. The revised tool went through a validation process
which included three phases . The final draft was then created and validated. Results :
The qualitati ve feedback questionnaire showed that clinicians felt the proposed nutrition
screening tool was capabl e of accurately reflecting nutrition risk most of the time to some
of the time. The validation study was still underway at the time this paper was written .
Conclusion: The new screening tool for children and adolescents with CF will be a
reliable , valid, and useful tool. It is anticipated that because clinical nutrition
professionals have been involved in the development process, the screening tool will be
widely accept ed and used. This would make it an integral part of the treatment process
for children and adolescents with CF aged 2 to 20.

Introduction:

Nom1al growth is the goal for all patients with CF. These individuals often
experience nutritional inadequacy resulting in impaired growth, suboptimal lung
function, and decreased longevity. (1,2) It is for these reasons that early identification of
nutritional inadequacy and intervention are needed. Nutrition screening is the first step in
the identification process.
The Cystic Fibrosis Foundation (CFF) recommends that patients with CF be seen
on a routine basis , every 3 months . The CF care team has the potential of having a
powerful and positive effect on appropriate growth and lung function. Patients' growth is
monitored and recorded at each visit. This facilitates the identification of suboptimal
growth and supports the provision of anticipatory counseling. Monitoring growth helps
identify CF patients at nutrition risk. It also helps facilitate early intervention and the
prevention of further decline. (1)
J\n effective nutrition screening tool has 5 characteristics . (3) It must be
applicable to the patient being screened. It is important that the nutrition screening can
be accomplished quickly and be able to provide readily available information. Reliability
and validity are crucial characteristics. The tool must be capable of assigning levels of
nutrition risk consistently to patients based solely on risk factors and established
paramet ers. This should occur independent from the clinician administering the screen.
The most current screening tool used for children and adolescents with CF was
not reliable and many felt it left too much room for clinical judgment. Another concern
was the terminology used by the tool when assigning nutritional status. Patients were
labeled as being "acceptable", "at-risk", or "nutritional failure" . (See Figure 1) It is for
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these reasons that a new screening tool was developed. The CFF sponsored efforts to
produce a new and improved nutrition screening tool for children and adolescents with
CF aged 2 to 20 years. ( 1)
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This paper will explain the development process of the new proposed screening
tool. It will also provide an overview of the genetic etiology and pathophysiology
responsible for the development of CF. Nutrition complications and recommended
interventions will be included which support the necessity of an accurate and valid
nutrition screening tool.
Methods:
The Cystic Fibrosis Foundation established a panel of experts for the purpose of
developing an evidence based screening tool to be used for children and adolescents with
C'F aged 2 to 20 years. Catherine McDonald, PhD, RD, was then given the responsibility
to create a screening tool based on the literature and parameters agreed upon by the
committee. She was responsible to create and format the actual nutrition screening tool
and then solicit feedback from other clinical nutrition experts for further refinement.
A team of pediatric dietitians at Primary Children's Medical Center participated
in a trial of a preliminary screening tool. The dietitians used the nutrition screening tool
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to screen six case studies for nutrition risk . There was a 92 . 1% agreement of assigned
nutrition risk. This exercise was useful because it revealed weaknesses in the tool and
pointed to areas requiring further clarification.

This trial made significant contributions

to the development of the nutrition screening tool.
Revisions were made and the tool was distributed to 17 pediatric dietitians
throughou t the United States . The team consisted of pediatric dietitians involved in the
provision of nutrition care for pediatric patients with CF. These nutrition professionals
were asked to use the screening tool on 5 to l 0 patients and then report on their
experience through a qualitative feedback questionnaire.
The participating clinicians reported that it took an average of 5 minutes to
comp lete th e screenin g process per patient. They also reported that they felt it was
capab le of accurate ly assessi ng and re flecting the nutrition risk of CF children and
adolescents most of the time to all of the time. Additional comments and suggestions
were solicited and encouraged. They were then used to edit and revise the nutrition
screening tool.
A new version was then distributed to the same 17 pediatric dietitians. They used
this dratt to screen four case studies. Three of the four case studies had an agreement of
100% for assigned nutrition risk. The fourth had an agreement of 71 %. This error helped
identify additional revisions necessary to ensure reliability and validity.
The screening tool was then edited and revised producing a final draft. The
proposed nutrition screening tool (figure 2) and an algorithm representing the
methodology (figure 3) were included on the following pages. The final draft and 18
case studie s were distributed to a new set of 7 registered dietitians.
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Patient Name:
Gender :
Age :
yr
mo
if > 9 years (F) and > 10 years (M)
Tanner Stage :
Weight for stature
Determine current BMI percentile for gender & age (CDC BMI chart): _____

_

Weight velocity
Curr ent wt (kg):_______
Dat e:____
_
Wt (kg) la~t clinic visit. ___ _
Dat e:
Net chan ge in w t : _ _ _ ______ _
Nu mber orda ys between we ights: __
Daily wt gain (gm/day) _ ______
(Round to nearest whole integer)
Expected weight gain per day (gm/day) ______
_
Height velocity
Current Ht (cm): ___
_ Date: ___
_
Ht (cm) ::: I year; S 2 yr prior to current visit: ____
Date :___
_
Net change in ht: ___
_
Number of years between height measurements __
_
Annual height gain (cm/year) _______
(Round to nearest whole integer)
Expected height gain per year (cm/year) _________
_

Expected

Daily Weight

Gain and Annual Height Gain

Minimally acce ptabl e rate of we ight and height ga in wh en
BMI is equal to or greater than 50 th percentile.
Average rate of weight and height gain at the 10th
percentile
DAILY WEIGHT
ANNUAL HEIGHT
GAIN
GAIN
(gm/d)
(cm/yr)
Age, y
Males
Females
Males
Females
2 .0-2.99
3
3
7
7
3.0- 3.99
3
3
6
6
4.0-4 .99
3
2
5
5
5.0-5.99
3
2
5
5
6.0-6.99
3
2
5
5
7.0 7 .99
3
4
~
4
8.0-8.99
3
4
3
4
9 .0-9 .99
2
3
4
4
10.0-10 .99
3
4
3
4
I 1.0-11.99
3
4
4
4
12.0-12 .99
4
I
4
3
13.0-13.99
4
<I
4
I
<l
14.0-14 .99
4
<l
3
<I
15.0- 15.99
<I
<I
1
<l
<1
16.0-16 .99
<1
<1
<l
<l
<1
17.0- 17.99
<I
18.0 - 18.99
4
2
.5
.l
19.0 - 19.99
3
I
.2
.I

Nutrition

Minimally acceptable rate of weight and height gain
th
when BMI is less than 50 percentile.
Average rate of weight and height gain at 50th
percentile
DAILY WEIGHT
ANNUAL
GAIN
HEIGHT GAIN
( •mid)
(cm/yr)
Age,y
Males
Females
Males
Females
2.0-2.99
5
5
9
9
3.0-3 .99
5
5
7
8
4 .0-4 .99
6
7
7
5
5.0-5.99
7
6
7
7
6.0-6.99
7
7
6
6
7 0-7 99
8
7
6
6
8.0-8 .99
8
8
6
6
9.0-9.99
9
8
5
6
10.0-10 .99
9
11
5
6
11.0-11.99
11
14
5
7
12.0-12.99
15
14
6
6
13.0-13 .99
18
11
8
3
14.0-14 .99
19
7
7
2
15.0-15 .99
13
4
4
1
16.0-16.99
8
<l
4
2
<1
17.0-17.99
5
2
I
18.0-18 .99
5
.1
3
.4
19.0-19.99
4
3
.2
.I

Risk:

0 Points
I Point
> 50%tile
<50 & :::'..10 ¾tile
> minimum
> 0 & < minimum
> minimum
>0 & < minimum
Total Points:
Nutrition Risk:
Figure 2 . Proposed Nutrition Screening Tool for Children and Adolescents aged 2
BMI Percentile
Daily Weight Gain
Annual Height Gain

2 Points
_:::I0¾tile
No wt ain/ Wt loss
No ht gain
to 20 .
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Step 1. Assign risk points.
for BMI Percentile

<50 & > 10 %tile
1 point

> 50%tile
0 point

::: 10¾tile
2 points

Step 2. Assign risk points
for daily weight gain.
Minimally acceptable
weight ga in detennined by
BM! % tile, age and gender.
Sec Table I

Daily
Weight
Gain

Wt gain 2: minimum
0 point

Wt gain > 0 & < minimum
1 point

No wt gain/ Wt loss
2 points

Step 3 . Assign risk points for
annual height gain.
Minimally acceptable height
gain dctennined by BMI
%tile , age and gender. See
Table 1 NOTE: Omit this

category if child is Tanner
stage V, female > 15 yr or
male> 17 yr.

I It ga in

2: m inimum

Ht gain >0 & < minimum
I point

0 point

Step 4. Tally total risk
points in steps 1-3.

Step 5. Determine nutrition risk category
Risk points Nutrition Risk
0

No identified factors
Low
Moderate
High

1
2-3
>4
,.

.

No ht gain
2 points

Results:
Th e qualitative feedback questionn aire showed that clinicians felt it was capable
of acc urately reflecting nutrition risk most of the time to some of the time. The
validation of the final draft had not been completed when this paper was written .
Discussion:
Cystic fibrosis (CF) is the most common autosomal recessive disorder affecting
the Caucasian population.

[t

affects 1 in 2,500 live births. The median life expectancy

for thusc affected with this disease is 35 .2 years. The first publication in the United
States describing CF was in 1938 , and the underlying genetic basis was not presented
until 1989. CF is caused by genetic mutations in the cystic fibrosis tansmembrane
regulator (CFTR) gene which results in defective chloride channels, causing the
formation of excess ive mucous in the lungs and the gastrointestinal system . This mucous
has several nutrition related conseq uence s, such as, nutrient malabsorpti on and
malnutriti on, fat solubl e vitamin defici enc y, osteoporosis, CF related diabetes , impaired
lung function , decreased quality oflife, and early death. (2)
Genetic Etiology:
CF is an autosomal recessive disease. It results from a mutation in the cystic
fibrosis tansmembran e regu lato r (CFTR) gene. The CFTR gene is a single large gene
located on chromosom e 7q. It encodes for the CFTR protein. This protein is composed
of 1480 amino acids. It functions as an integral part of chloride channels located on the
surface of epithelial cell membranes. These cAMP regulated channels assist in the
regulation of chloride and sodium transport. (2,4)
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CF is due to a mutation or mutations in the CFTR gene. There have been more
that 1200 sequence changes identified which result in clinical disease. The type of
sequence change and resulting genetic mutation dictates the severity of the disease.
There are four classes of CFTR gene mutations:
1. Defective protein production: Premature termination of the mRNA can result

from a splice-site , frameshift, or nonsense mutation. The result is a complete
absence of the CFTR protein.
2. Defective protein processing: The CFTR protein is unable to locate and attach
to the correct cellular location.
3. Defective regulation: The protein has decreased channel activity in response

to ATP.
4 . Dcf'cctive conduction: The protein is produced and attached correctly to the
cell surface. Chloride currents are generated in response to cAMP
stimulation . The mutations cause a reduction in the rate of ion flow and the
duration of channel opening . (4)
Pathophysiology:
The exocri ne glands are mo st affected by the genetic mutations in the CFTR
prot ein. Alte red sodium and chloride channel regulation leads to abnormal physical and
chemical secretions . This abnormality manifests itself in the respiratory tract, sweat and
salivary glands, pancreas, intestine, liver, and reproductive tract. These systems produce
abnonnally thick mucus which obstructs glands and ducts.
Impaired lung function is one of the biggest obstacles patients with CF face.
Malfunctions in the CFTR protein result in defective cAMP dependent chloride secretion
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from the respiratory epithelium. This failure of CFTR-mediated regulation of chloride
channel activity leads to increased airway lumen absorption of sodium. The result is an
alteration in airway secretions, which are thick and difficult to clear.
In addition to congestion , the high chloride concentration of epithelial secretions
may also leave the patient more susceptibl e to infection with unique bacteria.
Pseudomonas aeruginosa, Haemophilus influenzae , and Staphylococcus aureus species
are some of the most commonly observed infections. This increased risk of infection is
thought to be due to the dependency of neutrophils and beta-defensins on normal chloride
concentrations. (4)
Abnonnal inflammation is another pulmonary related issue experienced by
patients with CF. The CFTR-expressing tissue from patients with CF has been analyzed.
Researchers have found that these tissues have altered fatty acid metabolism. The result
is elevated arachidonic acid and its metabolites . It is thought that these may contribute to
the abnorm al inflammation which is characteristic of CF . (5)
In addition to pulmonar y complication s, CF patients often experience malfunction
within their digestive system. The thick mucus acts as a plug prev enting and limiting
pancreatic secretions into the small intestine . The blockage decreases the amount of
pancreatic enzymes which are able to reach the small intestine, causing enzyme
insufficiency and maldigestion of food . The ultimate result is malabsorption and
malnutrition. It is estimated that 85% to 90% of the CF population experiences
pancr eatic insufficiency . (1,2)
Proper management of gastrointe stinal and pulmonary symptoms makes normal
weight and/or growth status achievable for individuals with CF . Another important
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factor which helps support appropriate growth is adequate nutrient and energy intake.
There are also psychosocial and financial issues which must be properly managed.
Malnutrition is observed when there is a discrepancy between nutrition needs and actual
dietary intake. (6) In 2004 , 23% of U.S. children with CF were less than the 10th
percentile weight for age and gender, and 22% of adults with CF aged 18 to 30 years are
below a body mass index (BMI) of 19. These statistics were found in the 2004 CFF
Patient Registry Report. (7)
There is evidence from population based studies indicating that normal weightfor-age, weight-for-height , and height-for-age percentiles are associated with better FEVI
and longc\ ity f'or adults and children with CF. (2) It is recommended that children with
CF strive to maintain nonnal weight and stature-for-age and gender. Adults should strive
to maintain normal weight-for-height. (2)
The CFF has made the following recommendations :
1. Individuals with CF should consume energy intakes 110 to 200% of standard
energy needs for the healthy general population . These elevated energy
recommendations are necessary to support weight gain at an age-appropriate rate.
2. Children with CF aged 1 to 12 years at risk for or with growth deficits should
receive intensive treatment including behavioral intervention in conjunction with
nutrition counseling.
3. Nutritional supplements (oral and enteral) should be given to children with CF
who experience growth deficit s and adults who experience weight deficits . This
supplementation will improve the rate of weight gain. (6)
Conclusion:

The CFF recently identified nutrition status as the leading indicator of lung
function and longe vity. ( 1,6) ;\ regist ered dietitian is a fundamental part of the CF care
team . ( l) Increased attention and efforts should be given to improving the nutrition status
of individuals with CF. Improved nutrition means improved lung function , longevity,
and quality of life.
The new screening tool for children and adolescents with CF will be a reliable,
valid , and useful tool. This is because the values and parameters are evidence based and
have been approv ed by a multidi scipline panel of experts. It is anticipated that because
nutrition clinicians have been involved in the development process, the screening tool
will be widely accepted and used. This would make it an integral part of the treatment
process for children and adolescents with CF.
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